



Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults \geq 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials

Jonathan I. Silverberg¹ · Charles W. Lynde^{2,3} · Katrina Abuabara⁴ · Cataldo Patruno⁵ · Anna de Benedetto⁶ · Haixin Zhang⁷ · Ryan B. Thomas⁷ · Gaëlle Bégo-Le-Bagousse⁸ · Faisal A. Khokhar⁷ · Jignesh Vakil⁹ · Ainara Rodríguez Marco¹⁰ · Noah A. Levit⁷

Accepted: 14 April 2023 / Published online: 17 May 2023
© Springer Nature Switzerland AG 2023

Publisher Correction to:

American Journal of Clinical Dermatology
<https://doi.org/10.1007/s40257-022-00754-4>

The Original Article was published online on 20 February 2023.

As a result of a publisher error, three percentage symbols were missing in the Graphical Abstract on page 2. The values (with percentage symbols) should read:

IGA 0/1 for dupilumab: 44%.

IGA 0/1 for placebo: 7%.

EASI-75 for placebo: 14%.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s40257-022-00754-4>.

✉ Noah A. Levit
noah.levit@regeneron.com

¹ Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA

² University of Toronto, Markham, ON, Canada

³ Lynderm Research, Markham, ON, Canada

⁴ Department of Dermatology, University of California San Francisco, San Francisco, CA, USA

⁵ Department of Health Sciences, Magna Graecia University, Catanzaro, Italy

⁶ Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA

⁷ Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA

⁸ Sanofi, Chilly-Mazarin, France

⁹ Sanofi, Bridgewater, NJ, USA

¹⁰ Sanofi, Madrid, Spain

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.